W J C C World Journal Clinical Cases Submit Manuscript httpswwwf6publishingcom World J Clin Cases 2021 November 16 932 97119721 DOI 1012998wjccv9i329711 ISSN 23078960 online MINIREVIEWS Current treatment strategies patients peritoneal cytology positive stage IV gastric cancer Augustinas Bausys Zilvinas Gricius Laura Aniukstyte Martynas Luksta Klaudija Bickaite Rimantas Bausys Kestutis Strupas ORCID number Augustinas Bausys 0000000318482960 Zilvinas Gricius 0000000254284761 Laura Aniukstyte 0000000237687382 Martynas Luksta 000000018023 9908 Klaudija Bickaite 00000003 39523223 Rimantas Bausys 0000 000347186810 Kestutis Strupas 000000021690937X Author contributions Bausys R Strupas K conceptualized designed work Bausys A Gricius Z Aniukstyte L Bickaite K performed literature review critical revision studies Bausys A Gricius Z Bickaite K Aniukstyte L prepared manuscript Bausys R Strupas K revised manuscript authors read approved final form manuscript Conflictofinterest statement The authors declare conflicts OpenAccess This article openaccess article selected inhouse editor fully peerreviewed external reviewers It distributed accordance Creative Commons Attribution NonCommercial CC BYNC 40 license permits distribute remix adapt build work noncommercially Augustinas Bausys Rimantas Bausys Department Abdominal Surgery Oncology National Cancer Institute Vilnius 08406 Lithuania Augustinas Bausys Martynas Luksta Clinic Gastroenterology Nephrourology Surgery Institute Clinical Medicine Faculty Medicine Vilnius University Vilnius 03101 Lithuania Zilvinas Gricius Laura Aniukstyte Klaudija Bickaite Faculty Medicine Vilnius University Vilnius 08406 Lithuania Kestutis Strupas Clinic Gastroenterology Nephrourology Surgery Institute Clinical Medicine Vilnius University Vilnius 03101 Lithuania Corresponding author Augustinas Bausys MD Surgeon Department Abdominal Surgery Oncology National Cancer Institute Santariskiu str 1 Vilnius 08406 Lithuania augustinasbausysgmailcom Abstract Gastric cancer GC common malignancies worldwide surgery remains potentially curative treatment option Although significant proportion GC patients distant metastases initial diagnosis Peritoneal dissemination common site metastases Positive peritoneal cytology Cy1 associated poor longterm outcomes patients considered stage IV macroscopic carcinomatosis absent Currently clear evidence optimal treatment distinct subpopulation stage IV cohort Available strategies vary palliative chemotherapy upfront gastrectomy This comprehensive review summarized current evidence different treatment strategies Cy1 GC including roles surgery systemic intraperitoneal chemotherapy Key Words Gastric cancer Positive peritoneal cytology Gastrectomy Systemic chemotherapy Intraperitoneal chemotherapy The Authors 2021 Published Baishideng Publishing Group Inc All rights reserved WJCC httpswwwwjgnetcom 9711 November 16 2021 Volume 9 Issue 32 Bausys A et al Treatment gastric cancer positive cytology license derivative works different terms provided original work properly cited use noncommercial See htt pcreativecommonsorgLicense sbync40 Specialty type Medicine research experimental CountryTerritory origin Lithuania Peerreview reports scientific quality classification Grade A Excellent A Grade B Very good 0 Grade C Good 0 Grade D Fair 0 Grade E Poor 0 Received June 20 2021 Peerreview started June 20 2021 First decision July 2 2021 Revised July 28 2021 Accepted September 15 2021 Article press September 15 2021 Published online November 16 2021 PReviewer An T SEditor Wang JJ LEditor A PEditor Xing YX Core Tip Positive peritoneal cytology Cy1 associated poor longterm outcomes patients considered stage IV macroscopic carcino matosis absent The evidence efficient treatment patients conflicting We review current knowledge outcomes different approaches Cy1 gastric cancers Citation Bausys A Gricius Z Aniukstyte L Luksta M Bickaite K Bausys R Strupas K Current treatment strategies patients peritoneal cytology positive stage IV gastric cancer World J Clin Cases 2021 932 97119721 URL httpswwwwjgnetcom23078960fullv9i329711htm DOI httpsdxdoiorg1012998wjccv9i329711 INTRODUCTION Gastric cancer GC remains important health care issue fifth common fourth deadly cancer worldwide1 Surgery potentially curative treatment option it23 Although 3040 GC patients distant metastases initial diagnosis typically candidates radical surgery45 Peritoneal dissemination common site metastases6 Peritoneal lavage cytology staging laparoscopy modern standard detect peritoneal spread visible peritoneal carcinomatosis PC detected79 Positive cytology Cy1 negative prognostic factor recurrence survival10 defined metastatic M1 factor Cy1 patients considered stage IV absence macroscopic carcinomatosis Current clinical practice guidelines European Society Medical Oncology ESMO11 National Comprehensive Cancer Network NCCN recommend palliative chemotherapy Cy1 patients possibility restaging treatment Although Japanese GC treatment guidelines distinguish Cy1 patients distinct subpopulation stage IV cohort suggest considering neoadjuvant chemotherapy followed D2 gastrectomy noncurative factors absent 12 Such discrepancies lack standardization arise gap current knowledge efficient treatment patients Cy1 stage IV GC Therefore review aimed summarize current evidence peritoneal dissem ination GC available treatment options Cy1 stage IV patients MECHANISMS OF PERITONEAL DISSEMINATION IN GC Patients locally advanced penetrates subserosal connective tissue serosa adjacent structures T3 T4 advanced Nstage GC unfavorable histological subtypes diffuse type andor signet ring cell component primary scirrhous type GC higher risk peritoneal metastases1314 The development metastases multistep process includes 1 Cancer cells detachment primary tumor 2 Survival microenvironment peritoneal cavity 3 Malignant cells attachment peritoneal mesothelial cells invasion basement membrane 4 Tumor growth onset neoangiogenesis15 However free intraperitoneal cancer cells seed peritoneum turn PC nodes Most cells die successful attachment peritoneum peritonealblood barrier15 Further mesothelium innermost monolayer peritoneum basic protective mechanism adhesion exogenous cells15 PC develops subpopulation free GC cells manage penetrate submesothelial space producing specific growth factors matrix metalloproteinases induce contraction mesothelial cells exposing submesothelial basement membrane15 The presence free GC cells peritoneal cavity represents initial stages PC development currently methods determine exact stage multistep process diagnosed Thus remains unclear treatment concept Cy1 patients aim treat present peritoneal disease aim prevent development Because controversies different strategies adopted Cy1 GC worldwide Figure 1 WJCC httpswwwwjgnetcom 9712 November 16 2021 Volume 9 Issue 32 Bausys A et al Treatment gastric cancer positive cytology Figure 1 Different available treatment options patients cytology positive gastric cancer noncurative factors HIPEC Hyperthermic intraperitoneal chemotherapy PIPAC Pressurized intraperitoneal chemotherapy IPC Intraperitoneal chemotherapy EIPL Extensive peritoneal lavage UPFRONT SURGERY FOR CY1 GC PATIENTS Surgery remains potentially curative treatment option GC3 However Cy1 represents stage IV disease despite technically resectable biological rationale surgery controversial The results randomized controlled trial RCT Japan Clinical Oncology Group JCOG 0705 Korea GC Association KGCA01 comparing gastrectomy chemotherapy vs chemotherapy advanced GC single noncurable factor showed advantage surgery patients PC1617 Nonetheless palliative chemotherapy associated disappointing longterm outcomes Cy1 patients represent distinct subpopulation GC patients peritoneal dissemination Therefore aggressive treatment strategies including surgical resections utilized patients centers Upfront radical gastrectomy followed adjuvant S1 monotherapy invest igated phase II singlearm CCOG0301 study enrolled 48 Cy1 GC patients multiple treatment centers Japan18 Longterm followup showed 5year overall OS relapsefree survival rates 26 21 respectively Peritoneal recurrence occurred 62 enrolled patients18 Similar results confirmed groups East1921 Kano et al19 presented retrospective study median followup 10 years Radical gastrectomy followed adjuvant S1 chemotherapy resulted 178 5year OS rate peritoneal recurrence rate 52919 Further study documented benefit adjuvant S1 monotherapy median survival increased 223 mo compared 118 mo surgery group19 The benefit adjuvant therapy confirmed study Korea Shim et al20 Adjuvant chemotherapy TS1 cisplatin oxaliplatin plus capecitabine XELOX oxaliplatin 5FU FOLFOX improved median diseasefree survival DFS 1163 vs 698 mo P 0001 OS 2550 vs 1211 mo P 000120 No significant differences observed regimen postoperative chemotherapy survival20 optimal regimen remains unclear Another retrospective study Komatsu et al21 analyzed upfront gastrectomy followed adjuvant S1 based chemotherapy 51 Cy1 GC patients special focus impact surgical radicality Radical gastrectomy D2 Lymphon odectomy superior compared palliative gastrectomy 5year OS 482 vs 182 respectively21 Further impact surgery Cy1 GC treatment WJCC httpswwwwjgnetcom 9713 November 16 2021 Volume 9 Issue 32 Bausys A et al Treatment gastric cancer positive cytology presented recent study China22 Fortyeight Cy1 GC patients underwent upfront gastrectomy 75 n 36 gastrectomy neoadjuvant chemotherapy 25 n 1222 The median OS DFS 22 165 mo respectively22 However study provide comparison longterm outcomes patients received upfront surgery neoadjuvant treatment 22 In contrast comparison performed Mezhir et al23 In Western cohort Neoadjuvant therapy failed improve DSS 17 vs 09 P 076 relatively small sample size upfront surgery n 29 neoadjuvant treatment groups n 23 taken consideration23 Together current evidence indicates radical upfront gastrectomy feasible Cy1 GC patients adjuvant chemotherapy necessary improve longterm outcomes Although evidence upfront surgery arises small scale Eastern studies Such treatment strategy needs investigation largescale highquality surgical trials including patients Western parts world UPFRONT SYSTEMIC THERAPY FOR CY1 GC PATIENTS As mentioned previously Cy1 GC represents stage IV disease ESMO NCCN guidelines suggest considering systemic treatment chemotherapy improves survival quality life compared best supportive care11 Doublet triplet platinumfluoropyrimidine combinations trastuzumab recommended firstline palliative treatment11 Although evidence appropriate chemotherapy regimen treat peritoneal metastases GC24 different schemes adopted clinical practice Several studies investigated rates conversion positive negative cytology following initial treatment systemic chemotherapy2325 The reported rates conversion varied 489 722 treatment platinumfluoropyrimidine combinations docetaxel trastuzumab 2325 Such conversion positive negative cytology results improved oncological outcomes Mezhir et al23 showed increased diseasespecific survival 25 vs 14 years converted negative cytology Similar Yasufuku et al25 Aizawa et al24 demonstrated improved 3year 769 vs 105 5year 346 vs 176 OS rates respectively The high rate conversions positive negative cytology clinical benefit proposes consider initial chemotherapy palliative neoadjuvant treatment Further study Badgwell et al26 suggested palliative treatment inferior neoadjuvant chemotherapy despite 416 patients treated underwent surgery point treatment Neoadjuvant therapy group showed notably higher 3year OS rate 12 compared 0 patients considered having incurable stage IV disease scheduled palliative therapy The upfront systemic therapy promising conversion cytological status achieved especially converted patients allocated surgical treatment The effective chemotherapy regimens optimal number cycles conversions remain unknown future studies elucidate unclarities INTRAPERITONEAL THERAPIES FOR CY1 GC PATIENTS As shown previously systemic chemotherapy neoadjuvant adjuvant setting plays important role improve Cy1 GC patients outcomes Although systemic chemotherapy considered limited efficacy peritoneal dissemination peritonealplasma barrier27 Therefore direct intraperitoneal therapies suggested effective alternative patients INTRAPERITONEAL CHEMOTHERAPY AND EXTENSIVE INTRAOPERA TIVE PERITONEAL LAVAGE The rationale intraperitoneal chemotherapy IPC application possibility achieve high local concentration keeping low systemic concentration cytotoxic drug28 These pharmacokinetic features method increase WJCC httpswwwwjgnetcom 9714 November 16 2021 Volume 9 Issue 32 Bausys A et al Treatment gastric cancer positive cytology therapeutic efficacy decrease systemic toxicity The possible limitation IPC PC limited penetration drug The maximum estimated depth drug penetration 3 5 mm actual penetration range cell layers millimeters28 Despite shortcoming method PC preclude eradication free intraperitoneal cancer cells Thus IPC invest igated attractive option Cy1 GC patients Imano et al29 conducted pilot clinicopathological study investigate intraperi toneal administration 80 mgm2 paclitaxel end radical D2 gastrectomy 10 Cy1 GC patients Pharmacokinetic analysis showed peak plasma concentration paclitaxel reach cytotoxic threshold level 01 molL intraperitoneal drug concentration 6773 folds higher29 Such IPC cleared peritoneal cytology viable cancer cells 24 48 h IPC29 Following radical surgery IPC majority patients received adjuvant S1 based chemotherapy29 Longterm outcome analysis showed promising 3years survival rate 56 peritoneal recurrence rate 3029 Further authors compared survival outcomes historical cohort received gastrectomy concluded IPC significantly improves survival Cy1 GC patients 29 Another study IPC Cy1 GC investigated additional benefit extensive peritoneal lavage EIPL30 Shimada et al30 study included 22 Cy1 GC patients underwent 1 Gastrectomy 2 Gastrectomy IPC 100 mg cisplatin 3 Gastrectomy IPC EIPL peritoneal cavity washing 10 Liters physiologic saline solution Postoperatively patients received adjuvant 5FU based chemotherapy30 Longterm outcomes analysis showed 2year OS rates 0 143 571 groups 1 2 3 respectively Further EIPL reduced peritoneal recurrence rate 429 compared 857 100 gastrectomy IPC gastrectomy groups respectively Cancer cell detection analysis peritoneal lavage reverse transcriptasepolymerase chain reaction RTPCR suggested 10 Liters physiologic saline optimal flush free cancer cells peritoneal cavity30 Because promising results retrospective study gastrectomy EIPL IPC strategy tested subsequent multicenter RCT 31 The study included 88 Cy1 GC patients randomly allocated previously mentioned treatment strategies31 This prospective study confirmed superiority EIPL IPC 5year OS increased 438 compared 46 0 IPC gastrectomy groups respectively Further EIPL IPC significantly reduced peritoneal recurrence rate 400 compared 793 IPC 897 gastrectomy groups After promising results retrospective study confirmed subsequent RCT authors recommended considering EIPLIPC therapy standard prophylactic strategy peritoneal dissemination Cy1 GC patients31 However conflicting data efficacy EIPL presented recent EXPEL study This highquality openlabel multicentre phase 3 surgical RCT conducted 22 hospitals South Korea China Japan Malaysia Hong Kong Singapore enrolled 800 patients evaluate potential benefit EIPL upfront radical gastrectomy cT34 GC32 However EIPL 10 Liters saline improve 3year OS 770 vs 767 HR 109 95CI 078152 P 062 DFS 648 vs 694 HR 112 95CI 086147 P 040 3year cumulative incidence peritoneal recurrence 79 vs 66 HR 133 95CI 073242 P 035 Moreover EPIL associated higher risk adverse events RR 158 P 00193233 HYPERTHERMIC IPC Hyperthermic IPC HIPEC available method peritoneal malignancy It combines benefit IPC potential advantages hyperthermia Experi mental clinical evidence indicates hyperthermia range 41 43 C destroys malignant cells selectively increasing number lysosomes lysosomal enzyme activity malignant cells leading increased destructive capacity 28 Also hyperthermia decrease blood flow malignant tumors contrast opposite effect normal tissues28 Such effects inhibition oxidative metabolism malignant cells promote cell death sensitive malignant cells28 Further heat promotes cytotoxic effect chemotherapeutical agents 28 Thus HIPEC widely investigated peritoneal disease treatment including studies Cy1 GC patients Metaanalysis randomized highquality nonrandomized trials HIPEC prevention treatment peritoneal disease GC patients difference 3year OS RR 099 P WJCC httpswwwwjgnetcom 9715 November 16 2021 Volume 9 Issue 32 Bausys A et al Treatment gastric cancer positive cytology 085 patients PC34 Although HIPEC obtained advantages preventing peritoneal metastases RR 063 95CI 045088 P 001 highrisk patients including Cy1 GC patients34 Also HIPEC applied neoadjuvant setting showed Badgwell et al35 singlearm phase II study Nineteen stage IV GC patients positive cytology n 6 limited PC n 13 received 5 cycles neoadjuvant laparoscopic HIPEC initial systemic chemotherapy In total seven 368 converted negative cytology PC 5 received radical gastrectomy35 It important emphasize conversion rate 666 4 6 patients Cy1 patients considerably high35 This aggressive treatment resulted 3year OS rate 435 median survival patients received gastrectomy 29 mo After encouraging results study Badgwell et al36 conducted singlearm phase II study aggressive approach Twenty patients limited PC n 14 Cy1 n 6 treated initial systemic chemotherapy followed 12 Laparoscopic HIPEC procedures subsequent gastrectomy cytoreduction intraoperative HIPEC36 Such aggressive treatment resulted 28 3year OS36 However important note subgroup Cy1 patients promising result treatment 50 n 3 Cy1 alive recurrencefree 3249 mo diagnosis Despite encouraging initial results HIPEC Cy1 patients lack data high quality largescale RCTs Currently ongoing phase III GASTRICHIP trial37 designed evaluate effect HIPEC patients high risk peritoneal recurrence including Cy1 patients neoadjuvant chemotherapy37 The longterm outcomes available 2023 results elucidate unclarities HIPECs role Cy1 GC patients34 PRESSURIZED IPC Another new emerging technique peritoneal disease pressurized IPC PIPAC During PIPAC laparoscopic access obtained create pneumoperi toneum 12 mmHg nebulized chemotherapy applied create therapeutic capnoperitoneum 30 min38 The rationale PIPAC includes 1 Optimization drug distribution applying aerosol liquid solution 2 Applying increased intraperitoneal hydrostatic pressure increase drug penetration target 3 Limiting blood outflow drug application3940 Further minimally invasive approach PIPAC allows multiple applications procedure objective reassessment response laparoscopy biopsies39 Similar laparoscopic HIPEC PIPAC utilized neoadjuvant setting combination systemic therapy Several retrospective prospective phase II studies suggested PIPAC safe promising option GC patients PC4144 lack data efficacy specific cohort Cy1 patients SYSTEMIC CHEMOTHERAPY TARGETED THERAPY AND IMMUNO THERAPY FOR CY1 GC PATIENTS All abovementioned treatment strategies considered experimental standard treatment option M1 GC remains palliative systemic therapy11 Doublet triplet platinumfluoropyrimidine combinations recommended fit patients M1 GC including Cy1 patients standard conventional chemotherapy options 11 Although treatment remains associated poor outcomes45 novel treatment options like targeted therapy immunotherapy patients One available options included clinical practice guideline trastuzumab monoclonal antibody targeting human epidermal growth factor receptor 2 HER2 It induces antibodydependent cellular cytotoxicity inhibits HER2 mediated signaling prevents cleavage extracellular domain HER246 Large scale ToGA RCT showed trastuzumab combination chemotherapy increases survival advanced M1 HER2positive GC patients47 A recent study showed trastuzumab deruxtecan humanized monoclonal antiHER2 antibody attached cytotoxic topoisomerase I inhibitor cleavable linker available effective thirdline treatment HER2 positive GC patients48 Some HER2 targeting agents lapatinib trastuzumab emtansine pertuzumab WJCC httpswwwwjgnetcom 9716 November 16 2021 Volume 9 Issue 32 Bausys A et al Treatment gastric cancer positive cytology available efficacy remains controversial49_52 Another available targeted therapy agent ramucirumab fully humanized monoclonal antibody vascular endothelial growth factor receptor 253 This angiogenesis inhibitor included treatment guidelines secondline treatment option patients M1 GC encouraging results REGARD RAINBOW studies5455 Another novel promising drug class M1 GC immune checkpoint inhibitors Some drugs improve antitumor Tcell activity inhibiting immune checkpoints programmed death1 receptor PD1 programmed deathligand 1 PDL1 PD1 expressed surface activated T cells regulate proliferation activation PDL1 major ligand PD 1 expressed cancers including GC cells5657 Nivolumab available immune checkpoint inhibitors recommended combination fluorou racilcapecitabine oxaliplatin M1 HER2 negative GC including Cy1 patients recent RCTs demonstrated efficacy first58 lines treatment 59 Pembrolizumab immune checkpoint inhibitor antitumor activity patients PDL1 positive GC A phase II KEYNOTE059 study showed promising activity manageable safety pembrolizumab monotherapy line treatment60 Although phase III RCT KEYNOTE062 failed improved survival pembrolizumab pembrolizumab plus chemotherapy compared chemotherapy previously untreated GC61 Despite promising results novel targeted therapy immunotherapy drugs M1 GC exact benefit distinct cohort Cy1 GC patients remains unclear current studies investigated distinct subpopulation Further studies needed elucidate potential novel systemic therapies patients LIMITATIONS OF THE CURRENT KNOWLEDGE AND PERSPECTIVES FOR FUTURE RESEARCH The knowledge provided current evidence limitations First available studies relatively small sample size Second different treatment strategies including upfront gastrectomy surgery neoadjuvant systemic therapy IPC described Cy1 GC lack studies compared Thus largescale international cohort studies comparing different treatments needed establish promising options After tested subsequent multicenter randomized control trials provide robust evidence efficient treatment Cy1 patients CONCLUSION Positive peritoneal cytology associated poor longterm outcomes GC patients Although current evidence indicates distinct subpopulation stage IV cohort benefit aggressive treatment palliative chemotherapy Available strategies include upfront gastrectomy followed adjuvant therapy neoadjuvant chemotherapy option different methods IPC utilization Although optimal treatment remains unclear lack comparative studies Thus clinical trials needed establish best treatment option Cy1 GC REFERENCES 1 2 3 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Bray F Global Cancer Statistics 2020 GLOBOCAN Estimates Incidence Mortality Worldwide 36 Cancers 185 Countries CA Cancer J Clin 2021 71 209249 PMID 33538338 DOI 103322caac21660 Stratilatovas E Baušys A Baušys R Sangaila E Mortality gastrectomy 10 year single institution experience Acta Chir Belg 2015 115 123130 PMID 26021945 DOI 10108000015458201511681081 Bausys R Bausys A Vysniauskaite I Maneikis K Stratilatovas E Strupas K Surgical treatment outcomes patients T1T2 gastric cancer age matter excellent treatment results expected World J Surg Oncol 2018 16 79 PMID 29661204 DOI 101186s1295701813884 WJCC httpswwwwjgnetcom 9717 November 16 2021 Volume 9 Issue 32 Bausys A et al Treatment gastric cancer positive cytology 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Bernards N Creemers GJ Nieuwenhuijzen GA Bosscha K Pruijt JF Lemmens VE No improvement median survival patients metastatic gastric cancer despite increased use chemotherapy Ann Oncol 2013 24 30563060 PMID 24121120 DOI 101093annoncmdt401 Zhang Y Lin Y Duan J Xu K Mao M Wang X A PopulationBased Analysis Distant Metastasis Stage IV Gastric Cancer Med Sci Monit 2020 26 e923867 PMID 32409630 DOI 1012659MSM923867 Shi B Lin H Zhang M Lu W Qu Y Zhang H Gene Regulation Targeted Therapy Gastric Cancer Peritoneal Metastasis Radiological Findings Dual Energy CT PETCT J Vis Exp 2018 PMID 29443079 DOI 10379156526 Nakajima T Harashima S Hirata M Kajitani T Prognostic therapeutic values peritoneal cytology gastric cancer Acta Cytol 1978 22 225229 PMID 281825 Bando E Yonemura Y Takeshita Y Taniguchi K Yasui T Yoshimitsu Y Fushida S Fujimura T Nishimura G Miwa K Intraoperative lavage cytological examination 1297 patients gastric carcinoma Am J Surg 1999 178 256262 PMID 10527450 DOI 101016s0002961099001622 Yamaguchi T Takashima A Nagashima K Makuuchi R Aizawa M Ohashi M Tashiro K Yamada T Kinoshita T Hata H Kawachi Y Kawabata R Tsuji T Hihara J Sakamoto T Fukagawa T Katai H Higuchi K Boku N Efficacy Postoperative Chemotherapy After Resection Leaves No Macroscopically Visible Disease Gastric Cancer Positive Peritoneal Lavage Cytology CY1 Localized Peritoneum Metastasis P1a A Multicenter Retrospective Study Ann Surg Oncol 2020 27 284292 PMID 31535301 DOI 101245s1043401907697x Allen CJ Newhook TE Vreeland TJ Das P Minsky BD Blum M Song S Ajani J Ikoma N Mansfield PF RoyChowdhuri S Badgwell BD Yield peritoneal cytology staging patients gastric gastroesophageal cancer J Surg Oncol 2019 120 13501357 PMID 31612494 DOI 101002jso25729 Smyth EC Verheij M Allum W Cunningham D Cervantes A Arnold D ESMO Guidelines Committee Gastric cancer ESMO Clinical Practice Guidelines diagnosis treatment follow Ann Oncol 2016 27 v38v49 PMID 27664260 DOI 101093annoncmdw350 Japanese Gastric Cancer Association Japanese gastric cancer treatment guidelines 2018 5th edition Gastric Cancer 2021 24 121 PMID 32060757 DOI 101007s1012002001042y Rau B Brandl A Piso P Pelz J Busch P Demtröder C Schüle S Schlitt HJ Roitman M Tepel J Sulkowski U Uzunoglu F Hünerbein M Hörbelt R Ströhlein M Beckert S Königsrainer I Königsrainer A Peritoneum Surface Oncology Group members StuDoQPeritoneum Registry German Society General Visceral Surgery DGAV Peritoneal metastasis gastric cancer results German database Gastric Cancer 2020 23 1122 PMID 31228044 DOI 101007s10120019009780 Thomassen I van Gestel YR van Ramshorst B Luyer MD Bosscha K Nienhuijs SW Lemmens VE Hingh IH Peritoneal carcinomatosis gastric origin populationbased study incidence survival risk factors Int J Cancer 2014 134 622628 PMID 23832847 DOI 101002ijc28373 Kanda M Kodera Y Molecular mechanisms peritoneal dissemination gastric cancer World J Gastroenterol 2016 22 68296840 PMID 27570420 DOI 103748wjgv22i306829 Fujitani K Yang HK Kurokawa Y Park DJ Tsujinaka T Park BJ Fukuda H Noh SH Boku N Bang YJ Sasako M Lee JI Gastric Cancer Surgical Study Group Japan Clinical Oncology Group Korea Gastric Cancer Association Randomized controlled trial comparing gastrectomy plus chemotherapy chemotherapy advanced gastric cancer single noncurable factor Japan Clinical Oncology Group Study JCOG 0705 Korea Gastric Cancer Association Study KGCA01 Jpn J Clin Oncol 2008 38 504506 PMID 18617536 DOI 101093jjcohyn058 Jamel S Markar SR Malietzis G Acharya A Athanasiou T Hanna GB Prognostic significance peritoneal lavage cytology staging gastric cancer systematic review metaanalysis Gastric Cancer 2018 21 1018 PMID 28779261 DOI 101007s101200170749y Kodera Y Ito S Mochizuki Y Ohashi N Tanaka C Kobayashi D Kojima H Matsui T Kondo K Fujiwara M Longterm follow patients positive peritoneal lavage cytology final report CCOG0301 study Gastric Cancer 2012 15 335337 PMID 22527184 DOI 101007s1012001201563 Kano K Aoyama T Maezawa Y Nakajima T Ikeda K Yamada T Sato T Oshima T Rino Y Masuda M Ogata T Cho H Yoshikawa T The survival prognosticators peritoneal cytology positive gastric cancer patients received upfront gastrectomy subsequent S1 chemotherapy Int J Clin Oncol 2017 22 887896 PMID 28456896 DOI 101007s1014701711288 Shim HJ Kim HJ Lee SH Bae WK Hwang EC Cho SH Chung IJ Bang HJ Hwang JE Observational Study Peritoneal Washing CytologyPositive Gastric Cancer Gross Peritoneal Metastasis Patients Underwent Radical D2 Gastrectomy Sci Rep 2020 10 9549 PMID 32533084 DOI 101038s4159802066637y Komatsu S Shioaki Y Furuke H Ohta A Tsuji R Tanaka S Kumano T Imura KI Shimomura K Ikeda J Taniguchi F Ueshima Y Lee CJ Deguchi E Ikeda E Otsuji E Is curative gastrectomy justified gastric cancer cytology positive stage IV factor Langenbecks Arch Surg 2019 404 599604 PMID 31073759 DOI 101007s00423019017910 Kang WZ Zhong YX Ma FH Xue LY Xiong JP Ma S Li Y Xie YB Quan X Tian YT Survival outcomes prognostic indicators gastric cancer patients positive peritoneal wash cytology WJCC httpswwwwjgnetcom 9718 November 16 2021 Volume 9 Issue 32 Bausys A et al Treatment gastric cancer positive cytology 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 peritoneal metastasis radical gastrectomy World J Gastrointest Oncol 2021 13 2436 PMID 33510847 DOI 104251wjgov13i124 Mezhir JJ Shah MA Jacks LM Brennan MF Coit DG Strong VE Positive peritoneal cytology patients gastric cancer natural history outcome 291 patients Ann Surg Oncol 2010 17 31733180 PMID 20585870 DOI 101245s1043401011830 Aizawa M Nashimoto A Yabusaki H Nakagawa S Matsuki A Homma K Kawasaki T The clinical significance potentially curative resection gastric cancer following clearance free cancer cells peritoneal cavity induction chemotherapy Surg Today 2015 45 611617 PMID 25027056 DOI 101007s0059501409790 Yasufuku I Nunobe S Ida S Kumagai K Ohashi M Hiki N Sano T Conversion therapy peritoneal lavage cytologypositive type 4 large type 3 gastric cancer patients selected candidates R0 resection diagnostic staging laparoscopy Gastric Cancer 2020 23 319327 PMID 31350702 DOI 101007s10120019009940 Badgwell B Cormier JN Krishnan S Yao J Staerkel GA Lupo PJ Pisters PW Feig B Mansfield P Does neoadjuvant treatment gastric cancer patients positive peritoneal cytology staging laparoscopy improve survival Ann Surg Oncol 2008 15 26842691 PMID 18649106 DOI 101245s1043400800553 Bree E Michelakis D Stamatiou D Romanos J Zoras O Pharmacological principles intraperitoneal bidirectional chemotherapy Pleura Peritoneum 2017 2 4762 PMID 30911633 DOI 101515pp20170010 GonzálezMoreno S GonzálezBayón LA OrtegaPérez G Hyperthermic intraperitoneal chemotherapy Rationale technique World J Gastrointest Oncol 2010 2 6875 PMID 21160924 DOI 104251wjgov2i268 Imano M Imamoto H Itoh T Satou T Peng YF Yasuda A Kato H Nishiki K Shiraishi O Shinkai M Tsubaki M Yasuda T Nishida S Takeyama Y Okuno K Shiozaki H Impact intraperitoneal chemotherapy gastrectomy positive cytological findings peritoneal washings Eur Surg Res 2011 47 254259 PMID 22067579 DOI 101159000333803 Shimada S Tanaka E Marutsuka T Honmyo U Tokunaga H Yagi Y Aoki N Ogawa M Extensive intraoperative peritoneal lavage chemotherapy gastric cancer patients peritoneal free cancer cells Gastric Cancer 2002 5 168172 PMID 12378344 DOI 101007s101200200029 Kuramoto M Shimada S Ikeshima S Matsuo A Yagi Y Matsuda M Yonemura Y Baba H Extensive intraoperative peritoneal lavage standard prophylactic strategy peritoneal recurrence patients gastric carcinoma Ann Surg 2009 250 242246 PMID 19638909 DOI 101097SLA0b013e3181b0c80e Yang HK Ji J Han SU Terashima M Li G Kim HH Law S Shabbir A Song KY Hyung WJ Kosai NR Kono K Misawa K Yabusaki H Kinoshita T Lau PC Kim YW Rao JR Ng E Yamada T Yoshida K Park DJ Tai BC So JBY EXPEL study group Extensive peritoneal lavage saline curative gastrectomy gastric cancer EXPEL multicentre randomised controlled trial Lancet Gastroenterol Hepatol 2021 6 120127 PMID 33253659 DOI 101016S2468125320303150 Pocard M Reymond MA Peritoneal failure A new concept explain negative results randomized trials evaluating intraperitoneal therapies Pleura Peritoneum 2020 5 20200117 PMID 32566729 DOI 101515pp20200117 Desiderio J Chao J Melstrom L Warner S Tozzi F Fong Y Parisi A Woo Y The 30year experienceA metaanalysis randomised highquality nonrandomised studies hyperthermic intraperitoneal chemotherapy treatment gastric cancer Eur J Cancer 2017 79 114 PMID 28456089 DOI 101016jejca201703030 Badgwell B Blum M Das P Estrella J Wang X Ho L Fournier K Royal R Mansfield P Ajani J Phase II Trial Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion Peritoneal Carcinomatosis Positive Peritoneal Cytology Patients Gastric Adenocarcinoma Ann Surg Oncol 2017 24 33383344 PMID 28799004 DOI 101245s1043401760474 Badgwell B Ikoma N Murphy MB Wang X Estrella J RoyChowdhuri S Das P Minsky BD Lano E Song S Mansfield P Ajani J A Phase II Trial Cytoreduction Gastrectomy Hyperthermic Intraperitoneal Perfusion Chemotherapy Patients Gastric Cancer Carcinomatosis Positive Cytology Ann Surg Oncol 2021 28 258264 PMID 32556731 DOI 101245s10434020087395 Glehen O Passot G Villeneuve L Vaudoyer D BinDorel S Boschetti G Piaton E Garofalo A GASTRICHIP D2 resection hyperthermic intraperitoneal chemotherapy locally advanced gastric carcinoma randomized multicenter phase III study BMC Cancer 2014 14 183 PMID 24628950 DOI 1011861471240714183 Gamboa AC Winer JH Cytoreductive Surgery Hyperthermic Intraperitoneal Chemotherapy Gastric Cancer Cancers Basel 2019 11 PMID 31717799 DOI 103390cancers11111662 Nadiradze G Horvath P Sautkin Y Archid R Weinreich FJ Königsrainer A Reymond MA Overcoming Drug Resistance Taking Advantage Physical Principles Pressurized Intraperitoneal Aerosol Chemotherapy PIPAC Cancers Basel 2019 12 PMID 31877647 DOI 103390cancers12010034 Graversen M Detlefsen S Bjerregaard JK Fristrup CW Pfeiffer P Mortensen MB Prospective singlecenter implementation response evaluation pressurized intraperitoneal aerosol chemotherapy PIPAC peritoneal metastasis Ther Adv Med Oncol 2018 10 1758835918777036 WJCC httpswwwwjgnetcom 9719 November 16 2021 Volume 9 Issue 32 Bausys A et al Treatment gastric cancer positive cytology 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 PMID 29899763 DOI 1011771758835918777036 Struller F Horvath P Solass W Weinreich FJ Strumberg D Kokkalis MK Fischer I Meisner C Königsrainer A Reymond MA Pressurized intraperitoneal aerosol chemotherapy lowdose cisplatin doxorubicin PIPAC CD patients gastric cancer peritoneal metastasis phase II study Ther Adv Med Oncol 2019 11 1758835919846402 PMID 31205501 DOI 1011771758835919846402 Gockel I JansenWinkeln B Haase L Rhode P Mehdorn M Niebisch S Moulla Y Lyros O Lordick F Schierle K Wittekind C Thieme R Pressurized Intraperitoneal Aerosol Chemotherapy PIPAC Gastric Cancer Patients Peritoneal Metastasis PM Results SingleCenter Experience Register Study J Gastric Cancer 2018 18 379391 PMID 30607301 DOI 105230jgc201818e37 Ellebæk SB Graversen M Detlefsen S Lundell L Fristrup CW Pfeiffer P Mortensen MB Pressurized intraperitoneal aerosol chemotherapy PIPAC peritoneal metastasis gastric cancer descriptive cohort study Clin Exp Metastasis 2020 37 325332 PMID 32002724 DOI 101007s10585020100235 Kurtz F Struller F Horvath P Solass W Bösmüller H Königsrainer A Reymond MA Feasibility Safety Efficacy Pressurized Intraperitoneal Aerosol Chemotherapy PIPAC Peritoneal Metastasis A Registry Study Gastroenterol Res Pract 2018 2018 2743985 PMID 30473706 DOI 10115520182743985 Frattini F Rausei S Chiappa C Rovera F Boni L Dionigi G Prognosis treatment patients positive peritoneal cytology advanced gastric cancer World J Gastrointest Surg 2013 5 135 137 PMID 23710290 DOI 104240wjgsv5i5135 Hudis CA Trastuzumabmechanism action use clinical practice N Engl J Med 2007 357 3951 PMID 17611206 DOI 101056NEJMra043186 Bang YJ Van Cutsem E Feyereislova A Chung HC Shen L Sawaki A Lordick F Ohtsu A Omuro Y Satoh T Aprile G Kulikov E Hill J Lehle M Rüschoff J Kang YK ToGA Trial Investigators Trastuzumab combination chemotherapy versus chemotherapy treatment HER2 positive advanced gastric gastrooesophageal junction cancer ToGA phase 3 openlabel randomised controlled trial Lancet 2010 376 687697 PMID 20728210 DOI 101016S014067361061121X Shitara K Bang YJ Iwasa S Sugimoto N Ryu MH Sakai D Chung HC Kawakami H Yabusaki H Lee J Saito K Kawaguchi Y Kamio T Kojima A Sugihara M Yamaguchi K DESTINYGastric01 Investigators Trastuzumab Deruxtecan Previously Treated HER2Positive Gastric Cancer N Engl J Med 2020 382 24192430 PMID 32469182 DOI 101056NEJMoa2004413 Tabernero J Hoff PM Shen L Ohtsu A Shah MA Cheng K Song C Wu H EngWong J Kim K Kang YK Pertuzumab plus trastuzumab chemotherapy HER2positive metastatic gastric gastrooesophageal junction cancer JACOB final analysis doubleblind randomised placebo controlled phase 3 study Lancet Oncol 2018 19 13721384 PMID 30217672 DOI 101016S1470204518304819 ThussPatience PC Shah MA Ohtsu A Van Cutsem E Ajani JA Castro H Mansoor W Chung HC Bodoky G Shitara K Phillips GDL van der Horst T HarleYge ML Althaus BL Kang YK Trastuzumab emtansine versus taxane use previously treated HER2positive locally advanced metastatic gastric gastrooesophageal junction adenocarcinoma GATSBY international randomised openlabel adaptive phase 23 study Lancet Oncol 2017 18 640653 PMID 28343975 DOI 101016S1470204517301110 Satoh T Xu RH Chung HC Sun GP Doi T Xu JM Tsuji A Omuro Y Li J Wang JW Miwa H Qin SK Chung IJ Yeh KH Feng JF Mukaiyama A Kobayashi M Ohtsu A Bang YJ Lapatinib plus paclitaxel versus paclitaxel secondline treatment HER2amplified advanced gastric cancer Asian populations TyTANa randomized phase III study J Clin Oncol 2014 32 2039 2049 PMID 24868024 DOI 101200JCO2013536136 Hecht JR Bang YJ Qin SK Chung HC Xu JM Park JO Jeziorski K Shparyk Y Hoff PM Sobrero A Salman P Li J Protsenko SA Wainberg ZA Buyse M Afenjar K Houé V Garcia A Kaneko T Huang Y KhanWasti S Santillana S Press MF Slamon D Lapatinib Combination With Capecitabine Plus Oxaliplatin Human Epidermal Growth Factor Receptor 2Positive Advanced Metastatic Gastric Esophageal Gastroesophageal Adenocarcinoma TRIO013LOGiCA Randomized Phase III Trial J Clin Oncol 2016 34 443451 PMID 26628478 DOI 101200JCO2015626598 Young K Smyth E Chau I Ramucirumab advanced gastric cancer gastrooesophageal junction adenocarcinoma Therap Adv Gastroenterol 2015 8 373383 PMID 26557893 DOI 1011771756283X15592586 Fuchs CS Tomasek J Yong CJ Dumitru F Passalacqua R Goswami C Safran H Dos Santos LV Aprile G Ferry DR Melichar B Tehfe M Topuzov E Zalcberg JR Chau I Campbell W Sivanandan C Pikiel J Koshiji M Hsu Y Liepa AM Gao L Schwartz JD Tabernero J REGARD Trial Investigators Ramucirumab monotherapy previously treated advanced gastric gastro oesophageal junction adenocarcinoma REGARD international randomised multicentre placebocontrolled phase 3 trial Lancet 2014 383 3139 PMID 24094768 DOI 101016S0140673613617195 Wilke H Muro K Van Cutsem E Oh SC Bodoky G Shimada Y Hironaka S Sugimoto N Lipatov O Kim TY Cunningham D Rougier P Komatsu Y Ajani J Emig M Carlesi R Ferry D Chandrawansa K Schwartz JD Ohtsu A RAINBOW Study Group Ramucirumab plus paclitaxel WJCC httpswwwwjgnetcom 9720 November 16 2021 Volume 9 Issue 32 Bausys A et al Treatment gastric cancer positive cytology 56 57 58 59 60 61 versus placebo plus paclitaxel patients previously treated advanced gastric gastro oesophageal junction adenocarcinoma RAINBOW doubleblind randomised phase 3 trial Lancet Oncol 2014 15 12241235 PMID 25240821 DOI 101016S1470204514704206 Sexton RE Al Hallak MN Diab M Azmi AS Gastric cancer comprehensive review current future treatment strategies Cancer Metastasis Rev 2020 39 11791203 PMID 32894370 DOI 101007s10555020099253 Akyala AI Verhaar AP Peppelenbosch MP Immune checkpoint inhibition gastric cancer A systematic review Journal Cellular Immunotherapy 2018 4 4955 DOI 101016jjocit201805001 Janjigian YY Shitara K Moehler M Garrido M Salman P Shen L Wyrwicz L Yamaguchi K Skoczylas T Campos Bragagnoli A Liu T Schenker M Yanez P Tehfe M Kowalyszyn R Karamouzis MV Bruges R Zander T PazoCid R Hitre E Feeney K Cleary JM Poulart V Cullen D Lei M Xiao H Kondo K Li M Ajani JA Firstline nivolumab plus chemotherapy versus chemotherapy advanced gastric gastrooesophageal junction oesophageal adenocarcinoma CheckMate 649 randomised openlabel phase 3 trial Lancet 2021 398 2740 PMID 34102137 DOI 101016S0140673621007972 Kang YK Boku N Satoh T Ryu MH Chao Y Kato K Chung HC Chen JS Muro K Kang WK Yeh KH Yoshikawa T Oh SC Bai LY Tamura T Lee KW Hamamoto Y Kim JG Chin K Oh DY Minashi K Cho JY Tsuda M Chen LT Nivolumab patients advanced gastric gastro oesophageal junction cancer refractory intolerant previous chemotherapy regimens ONO453812 ATTRACTION2 randomised doubleblind placebocontrolled phase 3 trial Lancet 2017 390 24612471 PMID 28993052 DOI 101016S0140673617318275 Fuchs CS Doi T Jang RW Muro K Satoh T Machado M Sun W Jalal SI Shah MA Metges JP Garrido M Golan T Mandala M Wainberg ZA Catenacci DV Ohtsu A Shitara K Geva R Bleeker J Ko AH Ku G Philip P Enzinger PC Bang YJ Levitan D Wang J Rosales M Dalal RP Yoon HH Safety Efficacy Pembrolizumab Monotherapy Patients With Previously Treated Advanced Gastric Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE059 Trial JAMA Oncol 2018 4 e180013 PMID 29543932 DOI 101001jamaoncol20180013 Shitara K Van Cutsem E Bang YJ Fuchs C Wyrwicz L Lee KW Kudaba I Garrido M Chung HC Lee J Castro HR Mansoor W Braghiroli MI Karaseva N Caglevic C Villanueva L Goekkurt E Satake H Enzinger P Alsina M Benson A Chao J Ko AH Wainberg ZA Kher U Shah S Kang SP Tabernero J Efficacy Safety Pembrolizumab Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone Patients With Firstline Advanced Gastric Cancer The KEYNOTE062 Phase 3 Randomized Clinical Trial JAMA Oncol 2020 6 15711580 PMID 32880601 DOI 101001jamaoncol20203370 WJCC httpswwwwjgnetcom 9721 November 16 2021 Volume 9 Issue 32 Published Baishideng Publishing Group Inc 7041 Koll Center Parkway Suite 160 Pleasanton CA 94566 USA Telephone 19253991568 Email bpgofficewjgnetcom Help Desk httpswwwf6publishingcomhelpdesk httpswwwwjgnetcom 2021 Baishideng Publishing Group Inc All rights reserved